Abraxane

Phase 3Small molecule

Bristol-Myers Squibb

Abraxane is one of 194 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

193

Competitors

Pipeline

Status by Indication[3][1]

Indication

Triple-Negative Breast CancerRecruiting

Non-Small Cell Lung CancerCompleted

Breast CancerCompleted

Pancreatic CancerTerminated

Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting

Malignant TumorsRecruiting

Advanced/metastatic Solid TumorsActive, not recruiting

Triple-Negative Breast CancerPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 2

Completed

Breast CancerPhase 3

Completed

Pancreatic CancerPhase 2

Terminated

Gastric or Gastroesophageal Junction AdenocarcinomaPreclinical

Recruiting

Malignant TumorsPhase 1

Recruiting

Advanced/metastatic Solid TumorsPhase 1

Active, not recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Abraxane

Bristol-Myers Squibb

Phase 3

20 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Spravato

WWim Janssens

Preclinical

2 4

Duragesic

CCephalon

Preclinical

1 5

Nubain

AAultman Health Foundation

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 9

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 10

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Pancreatic Cancer

NCT02207465

Phase 1Recruiting

Malignant Tumors

NCT05631886

Phase 1Active, not recruiting

Advanced/metastatic Solid Tumors

NCT05631899

Phase 2Recruiting

Triple-Negative Breast Cancer

NCT07394387

Q1 2028

Phase 2Recruiting

Breast Cancer

NCT07284836

Q2 2028

PreclinicalRecruiting

Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05482893

Clinical

Trials by Indication[1]

Breast Cancer20 trials

ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer

Completed·OOrinove, Inc.·Phase 1/2·NCT03950570·58 enrolled

Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer

Completed·FFondazione Michelangelo·Phase 3·NCT01822314·632 enrolled

Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer

Unknown status·TTianjin Medical University·Phase 2/3·NCT01647672·60 enrolled

Show 17 more trials

T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

Completed·JJenny C. Chang, MD·Phase 1·NCT02073916·24 enrolled

Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

Completed·FFondazione Michelangelo·Phase 3·NCT02620280·278 enrolled

Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy

Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT07284836·30 enrolled

Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)

Completed·TThe Methodist Hospital Research Institute·Phase 2·NCT01446016·38 enrolled

Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer

Completed·UUniversity of Washington·Phase 2·NCT00821964·15 enrolled

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 1/2·NCT01938833·9 enrolled

Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer

Completed·—·N/A·NCT00308178·66 enrolled

Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer

Unknown status·ZZhejiang Cancer Hospital·N/A·NCT03647514·50 enrolled

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Completed·WWilliam Sikov MD·Phase 2·NCT00723125·60 enrolled

Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer

Completed·UUniversity of Miami·Phase 2·NCT00503906·30 enrolled

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Terminated·—·Phase 2·NCT01207102·10 enrolled

Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer

Completed·WWest Virginia University·Phase 1/2·NCT00442260·2 enrolled

Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer

Completed·FFudan University·Phase 2·NCT02687490·81 enrolled

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Completed·—·Phase 2·NCT00479674·41 enrolled

Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00107094·30 enrolled

Bioequivalence Study of Paclitaxel Protein-bound Particles for Injectable Suspension (Albumin-bound) in Breast Cancer Patients

Recruiting·CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·Phase 1·NCT07096869·28 enrolled

The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer

Unknown status·ZZhejiang Cancer Hospital·N/A·NCT03647280·50 enrolled

Pancreatic Cancer10 trials

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

Completed·—·Phase 1/2·NCT01506973·119 enrolled

Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy

Completed·UUniversity of Miami·Phase 2·NCT00691054·20 enrolled

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer

Active, not recruiting·—·Phase 1·NCT02207465·42 enrolled

Show 7 more trials

Treatment of Pancreatic Cancer With Abraxane

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02555813·317 enrolled

Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer

Terminated·OOlugbenga Olowokure·Phase 1/2·NCT01693276·3 enrolled

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Completed·OOncoMed Pharmaceuticals, Inc.·Phase 1·NCT01189929·57 enrolled

Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer

Unknown status·PPD Dr. med. Volker Heinemann·Phase 1·NCT02975141·12 enrolled

A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer

Completed·TTheriva Biologics SL·Phase 1·NCT02045589·8 enrolled

Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer

Completed·JJean-Luc Van Laethem·Phase 1·NCT01715142·23 enrolled

A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Completed·—·Phase 1·NCT02030860·15 enrolled

Non-Small Cell Lung Cancer3 trials

Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy

Completed·—·Phase 2·NCT02303977·37 enrolled

Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02027428·427 enrolled

Prospective Trial to Assess Real-world Outcomes and Predictive Biomarkers of Response to Pembrolizumab With or Without Chemotherapy in Black Patients With NSCLC

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06745882·318 enrolled

Nab-paclitaxel2 trials

LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT02328105·11 enrolled

Scheduling Nab-paclitaxel With Gemcitabine

Completed·CCCTU- Cancer Theme·Phase 2·NCT03529175·146 enrolled

Metastatic Melanoma2 trials

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01933061

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00970996·10 enrolled

33 more indications

Small Cell Lung Cancer2 trials

Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00454324·30 enrolled

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

Withdrawn·GGU Research Network, LLC·Phase 2·NCT02662634

Adenocarcinoma2 trials

Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

Withdrawn·RRoyal Marsden NHS Foundation Trust·Phase 1/2·NCT03361319

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01730586·34 enrolled

Melanoma2 trials

Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study

Completed·—·Phase 2·NCT00462423·50 enrolled

Abraxane and Temodar Plus Genasense in Advanced Melanoma

Unknown status·GGenta Incorporated·Phase 1·NCT00409383·28 enrolled

Pancreatic Ductal Adenocarcinoma2 trials

MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma

Withdrawn·—·Phase 2·NCT04134468

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

Completed·OOncoMed Pharmaceuticals, Inc.·Phase 2·NCT02289898·207 enrolled

Metastatic Prostate Cancer2 trials

Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer

Terminated·TThe Methodist Hospital Research Institute·Phase 2·NCT00521781·14 enrolled

Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

Completed·KKaiser Permanente·Phase 2·NCT00284752·56 enrolled

Pancreatic Adenocarcinoma2 trials

A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma

Completed·—·Phase 2·NCT01839799·32 enrolled

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Terminated·AAnwaar Saeed·Phase 2·NCT05239182·7 enrolled

Ovarian Cancer2 trials

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

Completed·SSoutheastern Gynecologic Oncology·Phase 2·NCT00466986·40 enrolled

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Unknown status·ZZhongshan Hospital Xiamen University·Phase 2·NCT04590625·58 enrolled

Metastatic Head and Neck Cancer1 trial

Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab

Terminated·UUniversity of California, Irvine·Phase 2·NCT00319839·10 enrolled

Advanced Head and Neck Cancer1 trial

Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT00736944·30 enrolled

Patients With Advanced Solid Tumors1 trial

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Completed·TTheriva Biologics SL·Phase 1·NCT02045602·42 enrolled

Advanced Solid Tumors1 trial

Abraxane and Alimta in Advanced Solid Tumors

Terminated·UUniversity of California, Davis·Phase 1/2·NCT00470548·49 enrolled

Metastasis1 trial

Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis

Unknown status·SShandong Cancer Hospital and Institute·Phase 2·NCT04639271·100 enrolled

Bladder Cancer1 trial

Intravesicular Abraxane for Treatment-Refractory Bladder Cancer

Completed·—·Phase 1/2·NCT00583349·46 enrolled

Peritoneal Cancer1 trial

Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

Completed·AAccelerated Community Oncology Research Network·Phase 2·NCT00407563·48 enrolled

Cancer of the Head and Neck1 trial

Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

Terminated·—·Phase 1/2·NCT00570674·29 enrolled

Pancreatic1 trial

Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)

Terminated·CCCTU- Cancer Theme·Phase 2·NCT02124369·9 enrolled

Triple-Negative Breast Cancer1 trial

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07394387·39 enrolled

Malignant Tumors1 trial

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Recruiting·—·Phase 1·NCT05631886·10 enrolled

Advanced/Metastatic Solid Tumors1 trial

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Active, not recruiting·—·Phase 1·NCT05631899·9 enrolled

Advanced or Metastatic Solid Tumors1 trial

Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00520000·47 enrolled

Lymphoma1 trial

Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma

Terminated·WWashington University School of Medicine·Phase 1·NCT01555853·20 enrolled

Metastatic Colon Cancer1 trial

Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)

Completed·MMt. Sinai Medical Center, Miami·Phase 2·NCT00625573·29 enrolled

Advanced Urothelial Cancer1 trial

Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03240016·36 enrolled

Neoadjuvant1 trial

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

Completed·TThe Methodist Hospital Research Institute·Phase 2·NCT02073487·32 enrolled

Advanced Cancers1 trial

Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers

Completed·YYale University·Phase 1·NCT00473720·15 enrolled

Metastatic1 trial

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Terminated·RRutgers, The State University of New Jersey·Phase 1/2·NCT00934895·27 enrolled

Gemcitabine1 trial

Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine

Completed·NNathan Bahary, MD·Phase 2·NCT01978184·104 enrolled

Carboplatin1 trial

A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus

Completed·NNYU Langone Health·Phase 2·NCT02744898·23 enrolled

Lung Cancer1 trial

Abequolixron (RGX-104) and Durvalumab in Lung Cancer

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT05911308·1 enrolled

Advanced Solid Cancers1 trial

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Terminated·YYale University·Phase 1·NCT00337376·23 enrolled

Esophageal Cancer1 trial

Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer

Unknown status·FFujian Medical University Union Hospital·Phase 2·NCT05828381·33 enrolled

Bevacizumab1 trial

Abraxane/Bevacizumab

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT01821859·5 enrolled

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 Followed by a Multi-cohorT Study in Patients With Advanced Gastrointestinal Cancers, Including GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, Targeted Therapy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

Recruiting·PPhanes Therapeutics·Preclinical·NCT05482893·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 77 trial records for Abraxane. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Abraxane compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Abraxane. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Abraxane

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2028

Q2 2028

Trials by Indication[1]

Breast Cancer20 trials

Pancreatic Cancer10 trials

Non-Small Cell Lung Cancer3 trials

Nab-paclitaxel2 trials

Metastatic Melanoma2 trials

Small Cell Lung Cancer2 trials

Adenocarcinoma2 trials

Melanoma2 trials

Pancreatic Ductal Adenocarcinoma2 trials

Metastatic Prostate Cancer2 trials

Pancreatic Adenocarcinoma2 trials

Ovarian Cancer2 trials

Metastatic Head and Neck Cancer1 trial

Advanced Head and Neck Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Advanced Solid Tumors1 trial

Metastasis1 trial

Bladder Cancer1 trial

Peritoneal Cancer1 trial

Cancer of the Head and Neck1 trial

Pancreatic1 trial

Triple-Negative Breast Cancer1 trial

Malignant Tumors1 trial

Advanced/Metastatic Solid Tumors1 trial

Advanced or Metastatic Solid Tumors1 trial

Lymphoma1 trial

Metastatic Colon Cancer1 trial

Advanced Urothelial Cancer1 trial

Neoadjuvant1 trial

Advanced Cancers1 trial

Metastatic1 trial

Gemcitabine1 trial

Carboplatin1 trial

Lung Cancer1 trial

Advanced Solid Cancers1 trial

Esophageal Cancer1 trial

Bevacizumab1 trial

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News